Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Teva- Pharmaceutical Industries Ltd. ADR shares valued at $91,748 were sold by Jover Placid on Aug 01 ’25. At $15.16 per share, Jover Placid sold 6,053 shares. The insider’s holdings dropped to 6,774 shares worth approximately $0.12 million following the completion of this transaction.
Also, Hughes Eric A sold 52,742 shares, netting a total of over 799,437 in proceeds. Following the sale of shares at $15.16 each, the insider now holds 0 shares.
Before that, Jover Placid had added 6,053 shares to its account. In a trade valued at $91,748, the Officer bought Teva- Pharmaceutical Industries Ltd. ADR shares for $15.16 each.
As published in their initiating research note from Goldman on June 06, 2025, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] has been a Buy and the price target has been revised to $24. Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in late May. As of May 12, 2025, JP Morgan has increased its “Neutral” rating to a “an Overweight” for TEVA. Earlier on July 10, 2024, Argus upgraded its rating. Their new recommendation was “a Buy” for TEVA stock which previously was a “a Hold”.
Analyzing TEVA Stock Performance
On last trading session, Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] rose 0.28% to $17.61. The stock’s lowest price that day was $17.33, but it reached a high of $17.63 in the same session. During the last five days, there has been a surge of approximately 2.32%. Over the course of the year, Teva- Pharmaceutical Industries Ltd. ADR shares have dropped approximately -3.56%. Shares of the company reached a 52-week high of $22.40 on 01/28/25 and a 52-week low of $12.47 on 04/10/25.
Support And Resistance Levels for Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
According to the 24-hour chart, there is a support level at 17.42, which, if violated, would cause prices to drop to 17.22. In the upper region, resistance lies at 17.72. The next price resistance is at 17.82. RSI (Relative Strength Index) is 61.76 on the 14-day chart, showing neutral technical sentiment.
Is Teva- Pharmaceutical Industries Ltd. ADR subject to short interest?
Stocks of Teva- Pharmaceutical Industries Ltd. ADR saw a sharp rise in short interest on 2025-07-31 jumping by 10.02 million shares to 49.89 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 39.87 million shares. A jump of 20.09% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.27 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.27.
Which companies own the most shares of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)?
In terms of Teva- Pharmaceutical Industries Ltd. ADR share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 25.28% from the previous closing price of $17.56. Analysts anticipate Teva- Pharmaceutical Industries Ltd. ADR stock to reach 28 by 2025, with the lowest price target being 10. In spite of this, 8 analysts ranked Teva- Pharmaceutical Industries Ltd. ADR stock as Buy at the end of 2025. On March 08, 2024, JP Morgan assigned a price target of “a Neutral” to the stock and upgraded coverage with a $14.
